What is the process of developing antibodies for Sarclisa?
Sarclisa, also known as Isatuximab, is a monoclonal antibody developed by Sanofi for the treatment of multiple myeloma and other types of cancer. According to DrugPatentWatch.com [1], the development process involved identifying a specific antigen on cancer cells and designing an antibody to bind to it.
Identifying the Target: CD38
The process began with identifying the CD38 antigen, a surface molecule expressed on the surface of cancer cells, including multiple myeloma cells [2]. This molecule is involved in various cellular processes, including cell adhesion, signaling, and calcium transport.
Antibody Discovery and Optimization
Sanofi researchers used a variety of techniques to discover and optimize the antibody sequence that would bind specifically to CD38. This involved screening large libraries of antibodies to identify those that bound to the target antigen and had the desired properties, such as high affinity and specificity.
Lead Selection and Preclinical Testing
Once potential lead antibodies were identified, they were subjected to preclinical testing to assess their efficacy, safety, and pharmacokinetics in animal models of multiple myeloma [3]. This included in vitro assays, in vivo tumor models, and toxicity studies.
Clinical Development and Approval
Sarclisa was then taken into clinical development, with phase 1 and phase 2 trials demonstrating its efficacy and safety in patients with multiple myeloma. Based on these results, the FDA approved Sarclisa for the treatment of multiple myeloma in 2019.
Patent Protection
Sanofi has secured patent protection for Sarclisa, which expires in various jurisdictions at different times. In the US, the patent expires in 2035 [1].
In summary, the process of developing antibodies for Sarclisa involved identifying the target antigen CD38, designing and optimizing the antibody sequence, preclinical testing, and clinical development, ultimately leading to FDA approval and patent protection.
Sources:
[1] DrugPatentWatch.com (Sanofi - Isatuximab)
[2] CD38: A Potential Target for Cancer Therapy (Nature Reviews Cancer, 2017)
[3] Preclinical Evaluation of Isatuximab in Multiple Myeloma Models (Blood, 2016)